Adamis Pharmaceuticals Corp - FORM 10-K - EX-32.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - April 15, 2021

Attached files

file filename
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corpadmp-10k_123120.htm
EX-32.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex32-2.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex31-2.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex31-1.htm
EX-23.2 - CONSENT OF MAYER HOFFMAN MCCANN P.C. - Adamis Pharmaceuticals Corpex23-2.htm
EX-23.1 - CONSENT OF BDO USA, LLP - Adamis Pharmaceuticals Corpex23-1.htm
EX-21.1 - SUBSIDIARIES - Adamis Pharmaceuticals Corpex21-1.htm
EX-10.73 - PROMISSORY NOTE DATED MARCH 15, 2021 - Adamis Pharmaceuticals Corpex10-73.htm
EX-10.72 - LEASE AGREEMENT - Adamis Pharmaceuticals Corpex10-72.htm
EX-10.20 - FIRST AMENDMENT TO LEASE - Adamis Pharmaceuticals Corpex10-20.htm
EX-4.6 - DESCRIPTION OF CAPITAL STOCK - Adamis Pharmaceuticals Corpex4-6.htm
 

Adamis Pharmaceuticals Corporation 10-K

 

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

 

The undersigned, Dennis J. Carlo, the Chief Executive Officer of Adamis Pharmaceuticals Corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

 

   (1) the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
   
   (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  /s/ DENNIS J. CARLO
  Dennis J. Carlo
  Chief Executive Officer

 

Dated: April 15, 2021

 

This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

   

Stock widget

Investing forum

Adamis Pharmaceuticals Corp Reports